Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic Review

Sara Sadeghi¹, Yasamin Kalantari², Sima Shokri³, Morteza Fallahpour³, Nahid Nafisi⁴, Azadeh Goodarzi⁵&⁶*

¹ Department of Pediatrics, Division of Dermatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
² Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
³ Department of Pediatrics, Allergy and Clinical Immunology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
⁴ Department of General Surgery, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
⁵ Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
⁶ Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Iran Jordan Dermatology and Hair Transplantation Center, Tehran, Iran

*Corresponding author:
Azadeh Goodarzi M.D.
Department of Dermatology, Associate Professor of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Iran Jordan Dermatology and Hair Transplantation Center, Tehran, Iran
Azadeh_goodarzi1984@yahoo.com, Goodarzi.a@iums.ac.ir

Authors Information:
1. Sara Sadeghi, M.D.
Division of Dermatology, Department of Pediatrics, University of Calgary, Alberta Children's Hospital, 28 Oki Dr NW, Calgary, AB, Canada
sarasadeghimd@gmail.com
sara.sadeghi1@ucalgary.ca
Cell phone: 0014039037600
ORCID: 0000-0002-1657-1487

2. Yasamin Kalantari, M.D.
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
Address: Razi Hospital, Vahdat-e-eslami Square, Tehran, Iran
Postal code: 1199663911
yasamin.kalantari@gmail.com
Cell phone: 0098912885894
ORCID: 0000-0001-8443-4591

3. Sima Shokri, M.D.
Assistant Professor,
Department of Pediatrics, Allergy and Clinical Immunology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Shokri.s@IUMS.ac.ir
Cell phone: 00989122951812
ORCID:0000-0002-2176-3934

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
4. Morteza Fallahpour, M.D.
Assistant Professor,
Department of Pediatrics, Allergy and Clinical Immunology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Fallahpour.morteza@yahoo.com
Cell phone: 00989111264407
ORCID: 0000-0002-5248-8312

5. Nahid Nafissi, M.D.
Department of General Surgery, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Nafissi.n@iums.ac.ir
Cell phone: 00989121939395
ORCID: 0000-0001-7454-9985

6. Azadeh Goodarzi, M.D.
Associate Professor of Dermatology,
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Iran Jordan Dermatology and Hair Transplantation Center, Tehran, Iran
Address: Rasool Akram Medical Complex, Sattarkhan Avenue, Niayesh Street, Tehran, Iran
Postal Code: 1445613131
azadeh_goodarzi1984@yahoo.com
goodarzi.a@iums.ac.ir
Cell Phone: 00989123882448
Phone Number: 00982166502040
ORCID: 0000-0002-1249-4429
Abstracts

**Backgrounds:** Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life.

**Aims and objectives:** To collect and summarize all data about the immune response, effectiveness, and safety of available COVID-19 vaccines for people aged 2 – 21 years old.

**Methods:** A thorough systematic review was performed on available publications in English language regarding immunogenicity, efficacy, and safety of COVID-19 vaccines in individuals aged 2 – 21 years old. Types of selected studies were clinical trials, observational studies, and cohort. Searched databases comprised Ovid Medline, Cochrane Library, Embase, Scopus, Web of Sciences, Google Scholar, and ClinicalTrials.gov website. Data extraction and analysis were performed in Microsoft Word software, version 16.56.

**Results:** The COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5 vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely.

**Conclusion:** Vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying disease, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is caused by coronavirus 2019 (COVID-19) and was announced as a global pandemic on March 11, 2020\(^1\). Children and adolescents are at risk of COVID-19 infection as likely as other age groups; however, children may manifest milder symptoms than adults\(^2\). Although the clinical course of COVID-19 infection is smoother in pediatrics, the disease can escalate to severe pulmonary involvement especially in those with underlying medical conditions\(^3\).

Multiple trials evaluated the efficacy and safety of vaccines against COVID-19 in healthy grown-ups as well as adults with comorbidities\(^4-9\). Likewise, vaccination against coronavirus can prevent serious outcomes or hospitalization following the natural infection\(^10\). Of note, children and adolescents have their education, safety, mental and physical wellness negatively affected which it makes vaccination crucial for them\(^11\).

All children and adolescents should be considered for COVID-19 vaccination for their own protection against the infection and its outcomes, and more importantly because they are part of the COVID transmission cycle\(^12, 13\). Several clinical trials supported the favorable immune response, effectiveness, and safety profiles of COVID-19 vaccines in healthy children and adolescents, and those with underlying medical conditions\(^14-16\). In the current study, we aimed to collect all the data about immunogenicity, efficacy, and safety of available COVID-19 vaccines to guide health care workers and families on vaccinating the younger population (2 – 21 years old).

2. Method and Materials

The current systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA).

2.1. Search Strategy

A systematic search was performed on databases including Ovid Medline, Cochrane Library, Scopus, Web of Sciences, Embase, Google Scholar, and ClinicalTrials.gov website until December 7\(^{th}\), 2021. The combination of employed keywords and MeSH terms is attached in the supplementary data (Table S1). A total of 9,369 publications were found in the primary search and 5,540 duplicates were removed in the first screening phase and 3,829 published studies
entered the next phase of screening. PRISMA flow diagram can be found in supplementary data (Figure S1).

2.2. Literature Screening

For the entire screening process, EndNote software, version 20, was utilized. In the first phase of screening, 5,540 duplicates were detected by EndNote and removed. In the second phase of screening, two investigators independently reviewed all the literature by reading titles and abstracts to ensure their quality to be included in data extraction, and remained duplicates were removed manually. Disagreements were resolved with discussion or the consensus of the corresponding investigator. In the last phase of screening, full texts were reviewed by one investigator and 22 publications plus two ongoing clinical trials, with released interim results, were selected for data extraction.

2.3. Inclusion and Exclusion Criteria

Criteria for inclusion of studies comprised full text, English language, human studies, pediatric and adolescent population (21 years old or younger), clinical trials, observational studies, cohort, case series and case reports. Further, criteria excluding studies out of the review included trials about adults (older than 21 years old), studies on animals or in vitro/ex vivo, reviews, consensus, or guidelines, and articles which were not about COVID-19 vaccination.

2.4. Data Extraction

Extracted data from studies that were included in the current review are (i) study characteristics (author, year, design of study, county, name, and type of the vaccine), (ii) participants characteristics (age, sample size, and underlying medical conditions), and (iii) results (immune response, efficacy, safety, and adverse reactions). Microsoft Word software, version 16.56, was utilized for data extraction. One investigator performed data collection process.

2.5. Bias Assessment and Quality Evaluation

Methodological quality of the included studies and risk of bias were independently assessed by two investigators. For these assessments, the National Institute of Health (NIH) Quality Assessment Tool for Observation Cohort and Cross-Sectional Studies\(^{17}\) and the NIH Quality Assessment Tool for Clinical Trials\(^{18}\) were utilized and the results can be found in supplementary data table S2.

2.6. Data Analysis
We systematically reviewed and described all the information about immunogenicity, efficacy, and safety of all available vaccines for healthy children and adolescents or those with underlying diseases in Microsoft Word software, version 16.56.

3. Results

A total of 3,829 publications remained after removing duplicates. Among these numbers, 3,616 studies did not meet the inclusion criteria and were excluded out from the study. A total of 207 publications were entered the last phase of screening and ultimately 22 studies were selected for data extraction. Meanwhile, two ongoing clinical trials with the released interim results met the criteria to be included. Consequently, data extraction revealed the results of vaccination of a total of 50,848 children and adolescents for the current systematic review.

3.1. Immunogenicity of COVID-19 Vaccines in Pediatrics and Adolescents

A total of 12 publications plus two ongoing clinical trials investigated the immunogenicity of COVID-19 vaccines in participants aged 2 - 21 years old. Two other studies extended the age of their participants to 26 and 26.8 years old while assessing the immunologic response of the vaccination in pediatric groups (19, 20). Ali and Berman et al. (21) reported 98.8% serologic response to mRNA-1273 (Moderna) vaccine in contributors aged 12 – 17 years old compared to 98.6% seroresponse in younger adults, and neutralizing antibodies (Ab) titers implied no inferiority in younger ages than in older. Frenck et al. (22) conducted a randomized clinical trial (RCT), studying the effect of BNT162b2 (Pfizer) in participants aged 12 – 15 years old and found a greater post-vaccination Ab titer compared to vaccinated younger adults and control group. Han et al. (23) also announced over 96% serologic response 28 days after two doses of CoronaVac (Sinovac) injection to individuals aged 3 – 17 years old. Meanwhile, they noticed a higher Ab detection with 3.0μg dose of vaccine injection than 1.5μg dose. Walter (24) revealed that 99.2% of Pfizer recipients aged 5 – 11 years old achieved serologic response a month after the second dose injection. Moreover, a study conducted by Xia et al. (25) on the effect of BBIBP-CorV (Sinopharm) among participants aged 3 – 17 years old reported 100% serologic response 56 days after vaccination. Noteworthy that produced Ab following the injection of 4μg and 8μg of Sinopharm were significantly higher than 2μg dosage. Furthermore, Zue et al. (26) enrolled an RCT about recombinant adenovirus type-5(Ad5)-vectored COVID-19 vaccine which revealed 98% - 100% immunologic response 84 days post-vaccination in the 6 – 17-year-old age group. The robust Ab response to Ad5-vectored vaccine was higher in pediatrics than in adults.
Interim results of an ongoing RCT (NCT04918797) on BBV152 (COVAXIN) revealed over 90% serologic response following vaccination in 2 – 18 years old contributors. Another ongoing RCT (NCT04796896) has been evaluating Moderna vaccine in 4,753 individuals aged 6 months – 12 years old, and the interim results reported 99.3% immunologic response one month after the second shot of vaccine.

3.1.2 Immunogenicity of COVID-19 Vaccines in Pediatrics and Adolescents with Underlying Conditions

Multiple studies evaluated the immunologic response to COVID-19 vaccines in pediatrics and adolescents with underlying clinical conditions as well as in healthy individuals. Amodio et al.\(^{(27)}\) in a case series of 21 patients, reported the effect of Pfizer vaccine in eight adolescents aged 16 – 21 years old, seven patients with common variable immunodeficiency (CVID), and one patient with unclassified Ab deficiency (unPAD). The serologic response in such patients after two doses of vaccine was significantly lower than in healthy individuals. Dailey et al.\(^{(19)}\) compared the serologic response of the natural COVID-19 infection to the immunogenicity of the several COVID-19 vaccines in Inflammatory bowel disease (IBD) patients. All patients in the latter study were under the treatment with infliximab, vedolizumab, or methotrexate and the employed vaccines were Pfizer, Moderna, and Johnson & Johnson (JNJ). The serologic response was 10 folds greater post-COVID vaccination compared to natural COVID-19 infection. In another study on adolescents with IBD, Spencer et al.\(^{(28)}\) observed that Moderna recipients developed a greater Ab response compared to Pfizer and JNJ recipients disregarding the type of immunosuppressant medication. Shire et al.\(^{(29)}\) also performed a study on 12 – 17-year-old patients with IBD treated with TNF-inhibitors. Patients received Pfizer vaccine and showed an acceptable Ab titer on follow-ups. Haskin et al.\(^{(20)}\) found 63% serorespose after two doses of Pfizer among kidney transplant recipients (KTRs) aged 13.5 – 26.8 years old. Noteworthy that a high proportion of patients without an acceptable Ab response had an eGFR<30 mL/min/1.73m\(^2\) and formerly received rituximab. Interestingly, KTRs with a history of natural COVID-19 infection developed higher immunologic responses compared to vaccinated KTRs. Macedoni et al.\(^{(30)}\) reported an acceptable serologic response after Pfizer vaccine in 16 – 22-year-old patients with type-1 diabetes mellitus. A total of 57 of Solid organ transplants aged 12 – 18 years old in a cohort study conducted by Qin et al.\(^{(31)}\), received Pfizer vaccine while were on multiple immunosuppressants and anti-metabolites. Serologic response was reported 56.8% after the first
dose and 73.3% after the second dose of vaccine. Revon-Riviere et al.\(^{(32)}\) revealed 80% and 90% seropositive response in patients with solid tumor malignancy after the first and second dose of Pfizer, respectively. The age of patients ranged 16 – 21 years old and they were on chemotherapy, targeted therapy, or immunotherapy.

### 3.2. Efficacy of COVID-19 vaccines in Pediatrics and Adolescents

The efficacy of Pfizer vaccine in participants aged 5 – 11 years old was reported 90.7% after the second dose\(^{(24)}\) and in individuals aged 12 – 15 years old was 100% \(^{(22)}\). In a study, assessing the effectiveness of Pfizer in 12 – 18—year-old adolescents, among 57 participants, only two patients were tested positive for COVID-19 infection, one patient before receiving the second dose and another one 46 days after the second dose\(^{(31)}\). In the category of Pfizer recipients with underlying medical conditions, adolescents with solid tumor malignancy did not develop COVID-19 infection after full immunization\(^{(32)}\).

Other vaccines such as Moderna, CoronaVac, and ZyCov-D were reported 93.3%, 65.5%, and 100% protection against COVID-19 infection in 12 – 19 years old participants, respectively \(^{(21, 33, 34)}\). Additionally, studies on Sinopharm and COVAXIN (NCT04918797) suggested protection efficacy against COVID-19 among 2 – 18-year-old individuals\(^{(25)}\).

### 3.3. Safety of COVID-19 Vaccines in Pediatrics and Adolescents

Reported adverse reactions were mild-to-moderate and self-limiting. The most common adverse reactions following vaccination of children and adolescents comprised injection site pain and erythema, headache, fatigue, fever, and chills\(^{(21-25, 27, 30, 32, 35)}\). In the meanwhile, no allergic reactions were reported in patients with a history of allergy to PEG-asparaginase and acute lymphoblastic leukemia after receiving Pfizer vaccine\(^{(36)}\).

In 16 – 25-year-old patients who were residents of a long care facility and received Pfizer, after the first dose 83.9% and following the second dose of vaccine 74.2% of patients presented mild adverse reactions such as discomfort/agitation, nausea/emesis, diarrhea, fever, chills, headache, and injection site erythema\(^{(37)}\). Further, Pfizer was administered in patients with juvenile inflammatory arthritis (JIA) aged 16 – 21 years old and no exacerbation of JIA was reported\(^{(38)}\). Among KTRs aged 13.5 – 26.8 years old, a non-significant decrease in eGFR were reported after vaccination with Pfizer\(^{(20)}\). Increased agitation and changed seizure pattern (becoming cluster) were observed transiently in Pfizer recipients aged 12 – 15 years old with
underlying neurologic conditions\textsuperscript{(39)}. Pfizer vaccine was also injected to 12 – 17-year-old patients with mental illness and no adverse reactions were reported from patients\textsuperscript{(40)}.

### 4. Discussion

Mass vaccination of children and adolescents against coronavirus can be the endgame for the current pandemic\textsuperscript{(41, 42)}. Trials about the immunogenicity of mRNA vaccines (Moderna and Pfizer) against COVID-19 revealed a great humoral immunity and more interestingly cell-mediated response in adults and children\textsuperscript{(43, 44)}. AstraZeneca, JNJ, and Novovax demonstrated a lower humoral response than mRNA vaccines\textsuperscript{(44)}. The immune response in pediatric age groups was reported 90% - 100% which was also higher and more durable than natural COVID-19 infection\textsuperscript{(21, 23, 24)}. Therefore, vaccination of children and adolescents is recommended.

Immunogenicity among children and adolescents with underlying conditions such as malignancy, IBD, transplant recipients, inherited immunodeficiency, and those on immunosuppressant and immunomodulator medications was revealed to be lower than healthy individuals\textsuperscript{(20, 30, 45, 46)}. This finding can be justified because of the relative immune system suppression. However, it was still an acceptable immune response to vaccinate this group of children and adolescents as they are more prone to show more severe forms of COVID-19 disease and its negative outcomes\textsuperscript{(46)}.

Full vaccination of people aged 16 years and older with mRNA vaccines provided over 90% and partial vaccination with such vaccines provided over 80% efficacy on protection against COVID-19\textsuperscript{(8, 47-49)}. Other vaccines for adults such as virus-vectored vaccines (Ad26.COV2.S\textsuperscript{(50)}, AZD1222\textsuperscript{(51)}, Ad5-vectored\textsuperscript{(52)}), inactivated vaccines (BBV152\textsuperscript{(53)}, CoronaVac\textsuperscript{(54)}), recombinant particles or nanoparticle\textsuperscript{(55)} (V-01\textsuperscript{(56)}, Novavax\textsuperscript{(57)}, CoVLP\textsuperscript{(58)}) reported also a significant efficacy in protection against moderate to severe COVID-19 infection. Meanwhile, vaccination of children and adolescents was reported approximately 100% effective. Vaccination in 12 – 18-year-old participants has been decreased the rate of hospitalization due to COVID-19 and its consequences among these age groups\textsuperscript{(10, 59)}.

The most common adverse reactions following COVID-19 vaccination in adult and pediatric age groups have been fatigue, body pain, injection site pain and erythema, headache, myalgia, nausea/emesis/diarrhea, fever, and joint pain\textsuperscript{(35, 60-62)}. More serious adverse effects such as transient myocarditis and myopericarditis have been primarily reported in male adolescents;
however, the incidence of such reactions is rare and most of the patients fully recovered without treatment\(^{(63-65)}\). Risk-benefit assessment for vaccination against COVID-19 determined an acceptable balance for vaccinating children and adolescents of both sexes\(^{(63, 65, 66)}\).

5. Conclusion

The current systematic review on 22 publications plus the interim results of two ongoing clinical trials about vaccinating children and adolescents aged 2 – 21 years-old that provided an overall result about the serologic response, efficacy, and safety of available vaccines. Vaccinating younger age groups can be helpful to end the current pandemic as kids have been a part of the COVID-19 transmission cycle. Moreover, broad vaccination of all age groups can help us to prevent other COVID-19 variants to be formed. The safety profiles of such vaccines are acceptable and make them great options to prevent COVID-19 infection in healthy children and adolescents or patients with underlying conditions such as malignancy.

6. Limitation and Recommendation

All reviewed studies about COVID-19 vaccines, especially in pediatric groups, are new and need more time to be evaluated about their long-term efficacy and safety. Further, more studies are required to assess the long-lasting immunity of such vaccines among pediatrics and the need for booster shots.

Key Points

1. COVID-19 infection is milder in children and adolescents; however, vaccination in these age groups is needed to end the current pandemic and prevent the formation of new variants.
2. COVID-19 infection can cause catastrophic consequences in kids with underlying medical conditions.
3. COVID-19 vaccines provided great immune response and effectiveness (approximately 100\%) in children and adolescents.
5. Serious adverse reactions such as myocarditis and myopericarditis are reported to be transient and most of the patients recovered without treatment or residual signs and symptoms.


Acknowledgment

The authors would like to appreciate Xurong (Rachel) Zhao, the librarian at Alberta Children’s Hospital, for her assistance in the database search. The authors would also like to express their gratitude to the authorities of Rasool Akram Medical Complex Clinical Research Development Center (RCRDC) for their technical and editorial assistance.

Authors Contribution

Contributions to the current study are SS in the design, database search, screening publications, literature review, quality evaluation, and bias assessment, and drafting the manuscript. YK in screening publications, literature review, quality evaluation, and bias assessment, and drafting the manuscript, and AG, S. Shokri, MF, and NN in drafting, reviewing, and revising the manuscript critically for importance intellectual content. All authors have read and approved the final version to be published and agreed to be accountable for all aspects of the work. All authors agreed on the order in which their names are listed in the manuscript.

Abbreviations

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA), antibodies (Ab), adenovirus type-5(Ad5), common variable immunodeficiency (CVID), unclassified pediatric antibody deficiency (unPAD), Inflammatory bowel disease (IBD), Johnson & Johnson (JNJ), kidney transplant recipients (KTRs), juvenile inflammatory arthritis (JIA)

Conflict of interest

The authors declared no conflict of interest.

Ethical Approval

Not applicable.

Funding Support

This research received no external funding.

Transparency declaration
Authors declare that the manuscript is an honest, accurate, and transparent. No important aspect of the study is omitted.

**Patients and Public Partnership**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

**Data Availability Statement**

All data produced in the present study are available upon reasonable request to the authors.

**References**


Figures and Legends

Table 1: Characteristics of included published studies (n=22)
Table 2: Characteristics of included ongoing clinical trials with released interim results (n=2)
### Tables

**Table 1: Characteristics of included published studies (n=22)**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Country</th>
<th>Study design</th>
<th>Sample size</th>
<th>Age</th>
<th>Name of vaccine</th>
<th>Vaccine type</th>
<th>Immune Response</th>
<th>Efficacy</th>
<th>Adverse reactions and safety (n or %)</th>
<th>Special consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alamer (35)</td>
<td>Saudi Arabia</td>
<td>Cross-sectional</td>
<td>965</td>
<td>12 – 18 y/o</td>
<td>BNT162b2</td>
<td>mRNA</td>
<td>N/A</td>
<td>60%</td>
<td>reported at least 1 side effect</td>
<td>10% had type 1 diabetes mellitus, sickle cell anemia or asthma</td>
</tr>
<tr>
<td>Ali and Berman (21)</td>
<td>USA</td>
<td>RCT²</td>
<td>3,732</td>
<td>12 – 17 y/o</td>
<td>mRNA-1273</td>
<td>mRNA</td>
<td>98.8% serologic response</td>
<td>93.3% (after second dose)</td>
<td>Injection site pain, headache, fatigue</td>
<td>None</td>
</tr>
<tr>
<td>Amodio (27)</td>
<td>Italy</td>
<td>Observational</td>
<td>21 (only one adolescent entered to the current review)</td>
<td>16 y/o</td>
<td>BNT162b2</td>
<td>mRNA</td>
<td>Significant lower Ab¹ titer than healthy individual</td>
<td>N/A</td>
<td>Injection site pain</td>
<td>CVID⁵ and Burkitt lymphoma in remission</td>
</tr>
<tr>
<td>Bickel (37)</td>
<td>USA</td>
<td>Observational</td>
<td>31</td>
<td>16 – 25 y/o</td>
<td>BNT162b2</td>
<td>mRNA</td>
<td>N/A</td>
<td>N/A</td>
<td>Mild adverse reactions (83.9% after the first dose and 74.2% after the second dose)</td>
<td>Long care facility residents</td>
</tr>
<tr>
<td>Dailey (19)</td>
<td>USA</td>
<td>Cohort</td>
<td>33</td>
<td>2 – 26 y/o</td>
<td>JNJ-78436735⁶ (n=5), BNT162b2 (n=21), mRNA-1273 (n=7)</td>
<td>Viral vector, mRNA</td>
<td>15-fold higher serologic response post-vaccination compared to wild infection</td>
<td>N/A</td>
<td>N/A</td>
<td>IBD⁷ receiving infliximab or vedolizumab</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Design</td>
<td>Sample Size</td>
<td>Age Range</td>
<td>Vaccine Type</td>
<td>Serologic Response</td>
<td>Injection Site Reaction</td>
<td>JIA Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>--------</td>
<td>-------------</td>
<td>------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dimopoulou (38)</td>
<td>Greece</td>
<td>Observational</td>
<td>21</td>
<td>16 – 21 y/o</td>
<td>BNT162b2 mRNA</td>
<td>N/A</td>
<td>N/A</td>
<td>Injection site reaction (74%), urticaria, no exacerbation of JIA³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frenck (22)</td>
<td>USA</td>
<td>RCT</td>
<td>2,260 (1,131 received vaccine, 1,129 received placebo)</td>
<td>12 – 15 y/o</td>
<td>BNT162b2 mRNA</td>
<td>Greater response in adolescents than in younger adults</td>
<td>100% after 2 doses, 3 cases of Covid between the first and second dose</td>
<td>Injection site pain, fatigue, headache, and fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Han (23)</td>
<td>China</td>
<td>RCT</td>
<td>552</td>
<td>3 – 17 y/o</td>
<td>CoronaVac (Sinovac) Inactivated virus</td>
<td>Over 96% of serologic response after both doses</td>
<td>N/A</td>
<td>Injection site pain (13%), fever (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haskin (20)</td>
<td>Israel</td>
<td>Observational</td>
<td>38</td>
<td>13.5 – 26.8 y/o</td>
<td>BNT162b2 mRNA</td>
<td>63% serologic response after both doses. A high proportion of patients with GFR²&lt;30 or previously treated with rituximab did not develop Ab</td>
<td>N/A</td>
<td>Injection site reaction, fever, fatigue, headache, non-significant decrease in GFR after vaccination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jara (33)</td>
<td>Chile</td>
<td>Cohort</td>
<td>38,225 (8,192 received 1 dose and 30,033 received both doses)</td>
<td>16 – 19 y/o</td>
<td>CoronaVac Inactivated virus</td>
<td>N/A</td>
<td>65.5% prevents of covid-19 infection, 87.5% of hospitalization, 90.3% of ICU admission, and 86.3% of covid-related death</td>
<td>N/A</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Location</td>
<td>Study Type</td>
<td>Age Range</td>
<td>Vaccine Type</td>
<td>Treatment</td>
<td>Diagnosis</td>
<td>Side Effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-----------</td>
<td>-----------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>King (39)</td>
<td>UK</td>
<td>Observational</td>
<td>12 – 15 y/o</td>
<td>BNT162b2 mRNA</td>
<td>N/A</td>
<td>N/A</td>
<td>Severe fatigue and discomfort combined with increased agitation, change in seizure type becoming clusters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macedoni (30)</td>
<td>-</td>
<td>Observational</td>
<td>16 – 22 y/o</td>
<td>BNT162b2 mRNA</td>
<td>Acceptable serologic response</td>
<td>N/A</td>
<td>Injection site reaction and pain, fever Type 1 diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark (36)</td>
<td>Canada</td>
<td>Cohort</td>
<td>12 – 17 y/o</td>
<td>BNT162b2 mRNA</td>
<td>N/A</td>
<td>N/A</td>
<td>No allergic reactions History of acute lymphoblastic leukemia and allergy to PEG10-asparaginase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moeller (40)</td>
<td>USA</td>
<td>Observational</td>
<td>12 – 17 y/o</td>
<td>BNT162b2 mRNA</td>
<td>N/A</td>
<td>N/A</td>
<td>No adverse effects were reported from patients Mental illness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qin (31)</td>
<td>USA</td>
<td>Cohort</td>
<td>12 – 18 y/o</td>
<td>BNT162b2 mRNA</td>
<td>Ab titers 56.8% positive after the first dose and 73.3% positive after the second dose</td>
<td>N/A</td>
<td>2 patients tested positive for mild Covid-19 (the first infected between 2 doses, the second 46 days after second dose) Solid organ transplant recipients on multiple immunosuppressants and anti-metabolites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Cohort</td>
<td>Age Range</td>
<td>Vaccine Type</td>
<td>Ab Titers</td>
<td>Covid</td>
<td>Side Effects</td>
<td>Other Treatments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>-----------</td>
<td>--------------</td>
<td>-----------</td>
<td>-------</td>
<td>--------------</td>
<td>-----------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revon-Riviere (32)</td>
<td>France Cohort</td>
<td>16 – 21 y/o</td>
<td>BNT162b2 mRNA</td>
<td>Ab titers were positive in 8/10 after the first dose and positive in 9/10 after the second dose</td>
<td>No patients developed Covid after immunization</td>
<td>Injection site pain (6), fever and chills</td>
<td>Solid tumor malignancy on chemotherapy, targeted therapy, or immunotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shire (29, 32)</td>
<td>Canada Cohort</td>
<td>12 – 17 y/o</td>
<td>BNT162b2 mRNA</td>
<td>Acceptable Ab response after vaccination</td>
<td>N/A</td>
<td>N/A</td>
<td>IBD treated with TNF inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spencer (28)</td>
<td>USA Cohort</td>
<td>≤21 y/o</td>
<td>JNJ-78436735 BNT162b2 mRNA-1273 Viral vector, mRNA</td>
<td>20 Patients checked for Ab after vaccination and those received Moderna had significantly higher titer of Ab</td>
<td>N/A</td>
<td>N/A</td>
<td>IBD on immunosuppressor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walter (24)</td>
<td>USA RCT</td>
<td>5 – 11 y/o</td>
<td>BNT162b2 mRNA</td>
<td>99.2% of participants achieved serologic response 1 month after the second dose</td>
<td>90.7% effective (3 cases of Covid-19 reported 7 days or more after the second dose)</td>
<td>Fever (1 case was severe), injection site reaction and pain (71 – 74%), severe fatigue (0.9%), headache (0.3%), chills (0.1%)</td>
<td>12% of participants had obesity and 8% had asthma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xia (25)</td>
<td>China RCT</td>
<td>3 – 17 y/o</td>
<td>BBIBP-CorV (sinopharm) Inactivated virus</td>
<td>100% serologic response on day 56 post-vaccination</td>
<td>Protection efficacy against Covid-19</td>
<td>Moderate fever (n=32), and cough (n=22)</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical trial number</td>
<td>Country</td>
<td>Study design</td>
<td>Sample size</td>
<td>Age</td>
<td>Name of vaccine</td>
<td>Vaccine type</td>
<td>Immune Response</td>
<td>Efficacy</td>
<td>Adverse reactions and safety (n or %)</td>
<td>Special consideration</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------------</td>
<td>--------------</td>
<td>-----------------</td>
<td>----------</td>
<td>--------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>NCT04918797</td>
<td>India</td>
<td>Clinical trial</td>
<td>526</td>
<td>2 – 18 y/o</td>
<td>BBV152 (COVAXIN)</td>
<td>Inactivated virus</td>
<td>Over 90% serologic response</td>
<td>Suggested protection like adults</td>
<td>Suggested safety like adults</td>
<td>Interim results were released</td>
</tr>
<tr>
<td>NCT04796896</td>
<td>USA</td>
<td>Clinical trial</td>
<td>4,753</td>
<td>6 months – 12 y/o</td>
<td>mRNA-1273²</td>
<td>mRNA</td>
<td>99.3% serologic response one month after the second dose</td>
<td>N/A</td>
<td>Mild to moderate fatigue, headache, fever, and injection site pain</td>
<td>Continue enrolling children 6 months to 6 y/o</td>
</tr>
</tbody>
</table>

²Moderna